Latest Healthcare News

Cann Group has boosted its private credit loan facility by $2 million to facilitate the early redemption of convertible notes, maintaining its debt restructuring momentum.

Germany’s Hesse State Office has issued new GMP guidance that questions the viability of fragmented medicinal cannabis supply chains, reinforcing ECS Botanics’ integrated manufacturing approach and potentially tightening market supply.

Orthocell has secured a strategic foothold in Thailand's $84 million nerve repair sector by appointing MediTime as exclusive Remplir distributor, leveraging established clinical networks to accelerate market penetration.

Racura Oncology has secured Bellberry HREC approval for its HARNESS-1 lung cancer trial, enabling expansion to additional Australian sites including Chris O’Brien Lifehouse and Austin Health, setting the stage for accelerated patient enrolment.

OncoSil Medical has submitted its Humanitarian Device Exemption application to the FDA for its OncoSil™ device targeting distal cholangiocarcinoma, entering the final review phase with a decision expected within 45 days.

Cyclopharm Limited delivered a record $17.1 million in revenue for 1H FY26, driven by a 73% surge in US Technegas® sales. However, delays in clinical guideline publication have pushed the short-term US installation target beyond 2026, while medium-term ambitions remain intact.

Telix Pharmaceuticals has gained FDA alignment to advance Part 2 of its ProstACT Global Phase 3 trial for TLX591-Tx in metastatic castration-resistant prostate cancer, setting the stage for U.S. enrolment pending regulatory approval.

BCAL Diagnostics has acquired a 10.2% stake in Genetic Signatures for $1.39 million, aiming to merge early cancer detection with infectious disease diagnostics and expand its international footprint.

Algorae Pharmaceuticals has been appointed as a supplier under a NSW Health public hospital supply contract, marking a strategic milestone despite uncertain immediate revenue impact.

Neurotech International has received Notices of Allowance from the USPTO for two patents covering its lead drug NTI164, reinforcing its intellectual property position as it advances Phase 3 trials for autism spectrum disorder.

Echo IQ has locked in a pivotal exclusive data licensing deal with Advara HeartCare, gaining access to as many as one million de-identified echocardiography studies, a move set to turbocharge its cardiovascular AI development.

OncoSil Medical secures a spot in the PALACROS consortium, advancing its OncoSil™ device through a cost-efficient Phase II trial targeting unresectable locally advanced pancreatic cancer.